Point-of-care glucose testing is a type of medical test that measures blood glucose levels directly at the patients location, such as at the bedside, instead of sending blood samples to a lab for analysis. It is primarily used for managing diabetes, a condition where the body struggles to regulate blood glucose levels. Products used in point-of-care glucose testing include strips, lancets, lancing devices, and meters.

Drivers: The point-of-care (POC) diagnostics market is expanding due to the rising availability of CLIA-waived tests.  These simple tests enable healthcare providers to conduct diagnoses in various settings without specialized training, providing immediate results crucial for timely patient care.  This growth is further fueled by the increasing number of available CLIA-waived POC tests.  Specifically, diabetes management is a key focus due to its high prevalence and associated risks, including increased COVID-19 mortality.  Limited healthcare access and a shortage of professionals, especially in Asia, are driving POC glucose testing adoption.  Favorable regulations like CLIA in the US, which allows testing in non-traditional settings, also contribute significantly to market growth by expanding the patient pool and improving patient outcomes.

Challenges: Product commercialization in the point-of-care diagnostics market is hindered by a strict regulatory approval process, ensuring safety, accuracy, and performance. Regulatory bodies like the FDA and CE marking require rigorous testing and clinical trials, leading to delays, high development costs, and barriers for smaller companies. Additionally, standardization between point-of-care and laboratory methods is challenging, as pre-analytical errors and increased risk of mistakes by non-doctors may limit the widespread adoption of POC testing.

Market Trends: The healthcare sectors move towards decentralization is driving rapid growth in point-of-care (POC) diagnostics.  By enabling healthcare practitioners to conduct on-site testing, POC diagnostics facilitates faster diagnoses and treatment decisions, improving patient care.  Furthermore, decentralized testing plays a crucial role in the timely identification and containment of infectious diseases. This increasing demand for POC diagnostic solutions presents significant market growth opportunities.

Abbott, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Nipro, Nova Biomedical, PlatInium Equity Advisors, LLC (Lifescan, Inc.), Prodigy Diabetes Care, LLC, and Trividia Health, Inc. 

By Product: Based on the Product, Global Point-of-Care Glucose Testing Market is segmented as; Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer CONTOUR Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Other.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.